扩展当前指南推荐的前列腺特异性抗原密度阈值以改善风险导向磁共振引导前列腺癌诊断的获益/危害平衡:基于社区多中心MR-PROPER研究
该研究基于前瞻性多中心MR-PROPER研究的MRI臂(996例疑似前列腺癌的活检初治男性),事后分析PSA密度阈值策略。结果显示,在PI-RADS 3男性中,MRI后PSA密度阈值≥0.20 ng/ml²较指南推荐的0.10 ng/ml²减少不必要的活检并维持肿瘤学安全;而MRI前PSA密度阈值≥0.10 ng/ml²可避免部分无效活检和MRI扫描,但安全边际较窄。
要点
- PI-RADS 3男性MRI后PSA密度≥0.20 ng/ml²可减少29%阴性活检,仅漏诊1.3% GG≥2癌。
- MRI前PSA密度≥0.10 ng/ml²避免30% MRI扫描,但漏诊9.6% GG≥2癌,安全边际窄。
- 在GG≥2检出率24%的社区诊断环境中,上述阈值可改善获益/危害比。
核心结论
- 在社区诊断环境中,对PI-RADS 3男性采用MRI后PSA密度阈值≥0.20 ng/ml²而非推荐的0.10 ng/ml²,可减少不必要的活检并维持肿瘤学安全。
- 对于MRI指征,MRI前PSA密度阈值≥0.10 ng/ml²支持有利的获益/危害比,但安全边际较窄。
研究设计与样本
- 研究为前瞻性多中心MR-PROPER研究MRI臂的事后分析。
- 纳入996例疑似前列腺癌的活检初治男性,均接受MRI及针对PI-RADS评分≥3的靶向活检。
主要发现
- GG≥2癌检出率为24%(239/996)。
- 假MRI阳性结果为47%(217/456;133例阴性活检和84例GG1癌)。
- 在PI-RADS 3男性中,MRI后PSA密度阈值≥0.20 ng/ml²未检出1.3%(0-2.7%;3/239)的GG≥2癌,同时避免29%(22-35%;38/133)的阴性活检,GG1癌检出率为3.6%(0-8.2%;3/84)。
- MRI前PSA密度阈值≥0.10 ng/ml²避免38%(31-44%;50/133)的无效活检、12%(6.1-17%;10/84)的GG1癌检出和30%(27-33%;301/996)的MRI扫描,但漏诊9.6%(5.4-14%;23/239)的GG≥2癌。
关键数值与推荐
- 对于PI-RADS 3男性,推荐采用MRI后PSA密度阈值≥0.20 ng/ml²而非指南推荐的0.10 ng/ml²,以减少不必要的活检并维持肿瘤学安全。
- 对于MRI指征,MRI前PSA密度阈值≥0.10 ng/ml²支持有利的获益/危害比,但安全边际较窄。
临床怎么用
- 在社区诊断环境中,对PI-RADS 3男性可考虑采用MRI后PSA密度阈值≥0.20 ng/ml²来减少不必要的活检。
- 对于MRI指征,可考虑MRI前PSA密度阈值≥0.10 ng/ml²,但需注意其安全边际较窄。
- 这些发现可用于风险适应策略,尤其在活检意愿低或癌症厌恶的环境中。
局限性
- 本研究为事后分析,结果需在前瞻性研究中验证。
- 研究基于MR-PROPER研究的MRI臂,可能受原研究设计限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: International guidelines recommend a risk-based magnetic resonance imaging (MRI)-directed diagnostic pathway in prostate cancer (PCa) suspected biopsy-naïve men to reduce overdiagnosis. Prostate-specific antigen (PSA) density has been suggested as a stratification tool for MRI or biopsy testing. This study aims to investigate the risk-based MRI-directed pathway with PSA density thresholds indicating MRI and/or targeted biopsy in PCa suspected men, reducing safely unproductive interventions. METHODS: A post hoc analysis was conducted in the MRI arm of the prospective multicentre MR-PROPER study, originally comparing diagnostic outcomes with a risk calculator-based approach. PSA density thresholding strategies were investigated in PCa-suspected biopsy-naïve men undergoing MRI and targeted biopsy for Prostate Imaging Reporting and Data System (PI-RADS) score ≥3. Outcomes were grade group (GG) ≥2 cancer detection, avoided MRI scans, negative biopsies, and GG1 cancer detection, also addressed by benefit-to-harm ratios. KEY FINDINGS AND LIMITATIONS: MR-PROPER included 996 PCa-suspected men in the MRI pathway (per-protocol analysis). The GG ≥2 cancer detection rate was 24% (239/996). False MR-positive results were obtained in 47% (217/456; 133 negative biopsies and 84 GG1 cancer cases). In PI-RADS 3 men, post-MRI PSA density thresholding at ≥0.20 ng/ml2 left 1.3% (0-2.7%; 3/239) GG≥2 cancer cases undetected, while avoiding 29% (22-35%; 38/133) negative biopsies and a 3.6% (0-8.2%; 3/84) GG1 cancer detection rate. To indicate MRI, pre-MRI PSA density thresholding at ≥0.10 ng/ml2 avoided 38% (31-44%; 50/133) unproductive biopsies, GG1 cancer detection in 12% (6.1-17%; 10/84), and 30% (27-33%; 301/996) MRI scans, incurring 9.6% (5.4-14%; 23/239) undetected GG ≥2 cancer cases. CONCLUSIONS AND CLINICAL IMPLICATIONS: In a community-based diagnostic setting (24% GG ≥2 disease), applying a post-MRI PSA density threshold of ≥0.20 rather than the recommended threshold of 0.10 ng/ml2 in men with PI-RADS 3 lesions reduces unnecessary biopsies while maintaining oncological safety. This improved the benefit-to-harm ratio of risk-based PCa diagnostics, particularly in cancer-averse settings. For MRI indication, a pre-MRI PSA density threshold of ≥0.10 ng/ml2 supports a favourable benefit-to-harm ratio, though with narrow safety margins. These findings may inform risk-adapted strategies, particularly in biopsy-averse settings.
引用
- Prinsen AMA, Wagensveld IM, Osses DF, et al. Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm Balance in Risk-based Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study. Eur Urol Oncol. 2025. PMID: 41318235. doi:10.1016/j.euo.2025.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。